John Gallina compensation by year
Elevance Health Summary Compensation Table · all 7 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|
| Salary | $768,173 | $794,712 | $820,192 | $845,192 | $890,385 | $919,231 | $944,231 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $2,629,315 | $2,437,580 | $2,437,749 | $2,437,632 | $2,812,665 | $3,937,532 | $4,312,731 |
| Option awards | $812,445 | $812,445 | $812,264 | $812,385 | $937,402 | $1,312,557 | $1,437,286 |
| Non-equity incentive | $1,172,232 | $993,390 | $902,211 | $1,183,269 | $1,375,111 | $1,323,692 | $1,314,369 |
| Pension and deferred compensation | $11,190 | $0 | $17,683 | $13,484 | $2,402 | $0 | $11,918 |
| All other | $85,628 | $115,739 | $118,954 | $109,773 | $123,315 | $148,825 | $144,881 |
| Total | $5,478,983 | $5,153,866 | $5,109,053 | $5,401,735 | $6,141,280 | $7,641,837 | $8,165,416 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Elevance Health, Inc. DEF 14A filed March 29, 2024, accession 0001156039-24-000050, and prior-year filings.
How this page was built: the Elevance Health, Inc. filed document, accession 0001156039-24-000050. Every figure is read from that document and cited to the page and table it appears in. Filed March 29, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 15,814 | $7,457,250 | — |
| PSU | 11,944 | $5,632,313 | — |
| Option | 11,782 | — | $469.03 |
| Option | 4,119 | — | $311.48 |
| Option | 7,730 | — | $451.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Elevance Health, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Elevance Health’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Gail Boudreaux | President and Chief Executive Officer | $21,889,039 |
| Mark Kaye | Executive Vice President and Chief Financial Officer | $12,359,201 |
| John Gallina · this page | Former Executive Vice President and Chief Financial Officer | $8,165,416 |
| Blair Todt | Executive Vice President, Chief Legal and Administrative Officer | $8,112,972 |
| Peter Haytaian | Executive Vice President and President of Carelon and CarelonRx | $6,978,051 |
| Felicia Norwood | Executive Vice President and President of Government Health Benefits | $6,475,408 |
The full Elevance Health compensation record
free company briefThis page is one person within Elevance Health's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Elevance Health proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Elevance Health's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.